Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes

In patients with autoimmune diabetes no significant differences were observed in glucose control, expressed as time in range evaluated by continuous glucose monitoring comparing the 3 days after Sars-Cov2 vaccine with the 14 days preceding the vaccine.

Detalles Bibliográficos
Autores principales: D'Onofrio, Luca, Coraggio, Lucia, Zurru, Annalisa, Carlone, Angela, Mignogna, Carmen, Moretti, Chiara, Maddaloni, Ernesto, Buzzetti, Raffaella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383474/
https://www.ncbi.nlm.nih.gov/pubmed/34450248
http://dx.doi.org/10.1016/j.diabres.2021.109022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383474/
https://www.ncbi.nlm.nih.gov/pubmed/34450248
http://dx.doi.org/10.1016/j.diabres.2021.109022

Ejemplares similares